Critical appraisal:Rotolo F, Dunant A, Le Chevalier T, Pignon JP, Arriagada R, IALT Collaborative Group 2014 1

From Cancer Guidelines Wiki
Jutta's tick icon.png This appraisal has been completed.


Article
Rotolo F, Dunant A, Le Chevalier T, Pignon JP, Arriagada R, IALT Collaborative Group. Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach. Ann Oncol 2014 Nov;25(11):2162-6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25193990.
Assigned to
User:Shawgi.sukumaran
Topic area
Guidelines:Lung cancer/Treatment/Non-small-cell stage II operable
Clinical question
Form
Form:Critical appraisal
Study design
randomised controlled trial
Level of Evidence
II

Section below only relevant for Cancer Council Project Officer

Edit appraisal assignment


Critical Appraisal

Article being appraised

Rotolo F, Dunant A, Le Chevalier T, Pignon JP, Arriagada R, IALT Collaborative Group. Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach. Ann Oncol 2014 Nov;25(11):2162-6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25193990.


Applicable clinical question

Key Facts

Study Design

randomised controlled trial

Study aims:

This study aimed to look at long term mortality data from subjects on the IALT study

Number of Patients:

1687

Reported outcome(s):

it reports that long term non-cancer mortality was higher in patients who received chemotherapy arm compared to the control

Results of outcome(s):

Hazard Ratio of non cancer mortality in the Treated arm compared to controls HR 3.6 (95% CI 2.2-5.9, P<0.001)

Comments on results:

The conclusion were based on a small total number of events

Includes an economic evaluation

no

Evidence ratings

Level of evidence

II

Risk of bias
Moderate risk of bias Comments: Please replace this text and include any additional comments in regards to your risk of bias rating

Risk of bias assessment: randomised controlled trial

Was the trial double-blinded?
Outcomes not blinded, substantial side-effects, or not reported.
Was the treatment allocation schedule concealed?
No concealment or unclear (e.g. no approach described, open randomisation lists, person doing recruitment tossing a coin).
Were all randomised participants included in the analysis?
No exclusions or survival analysis used with all subjects included (>95% follow-up for all groups).
The field below is not considered when calculating the risk of bias rating
How was the allocation schedule generated?
Adequate (e.g. random number table, computer random generator, coin tossing, card shuffling)
Size of effect
4 Reason for decision: Please replace this text and briefly describe the reasons for your rating
Relevance of evidence
1 Additional comments: Please replace this text and briefly describe the reasons for your rating
Result of appraisal

Jutta's tick icon.png Included



Comments

Long term side effects including the potential increased mortality risks should be taken into consideration while making clinical decisions regarding adjuvant chemotherapy

Completed by

Dr Shawgi Sukumaran